یک عمر خوانده بودیم
ها یا مهارگرهای آنزیم مبدل
آنژیوتانسین، اثر محافظتی روی کلیه‌ها دارند و مثلا در دیابتیک‌ها پیدایش
میکروآلبومینوری را به تاخیر می‌اندازند، امروز این دکتر
نفرولوژیست وبلاگ‌نویس
، در این پست خود لینکی به یکی از
مقاله‌های اخیر مجله
لنست داده . در این مقاله یک متا
آنالیز شرح داده شده است ، که بر طبق آن عنوان
شده این دسته دارویی در مقایسه با دیگر دسته‌های دارویی پایین آورنده فشار خون
مزیتی ندارند.

خوب ، حرف و حدیث در این باره زیاد
است و تا اطلاع ثانوی و تحقیقات بیشتر، به همان روال قبلی عمل می‌کنیم.

2 نظرات
  1. Armin می گوید

    Dear Dr, at least for diabetics, AceI is still a strong drug of choice. even u can find one very very recent article in Journal of HTN , Jan2006!
    Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.

    Burnier M, Zanchi A.

    Service de Nephrologie, Department of Medicine, Lausanne Switzerland.

    Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions. Individuals with diabetes are not only more likely to develop hypertension, dyslipidemia, and obesity, but are also at a significantly higher risk for coronary heart disease, peripheral vascular disease, and stroke. Angiotensin II plays a key pathophysiological role in the progression of diabetic renal disease, and blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II antagonists has therefore become an important therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Several studies have demonstrated the effects of angiotensin II antagonists on the reduction of albuminuria and the progression of renal disease from microalbuminuria to macroalbuminuria. More importantly, several endpoint trials have shown that the antiproteinuric effects of losartan and irbesartan translate into cardiovascular and renoprotective benefits beyond blood pressure lowering, thereby delaying the need for dialysis or kidney transplantation by several years. These and other studies indicate that angiotensin II antagonists not only improve survival and quality of life of patients with diabetic nephropathy, but also have the potential to reduce the substantial healthcare burden associated with managing these patients. ACEi also appear to exert similar beneficial effects in diabetic patients, but whether clinically significant differences in renoprotection or mortality exist between angiotensin II antagonists and ACEi in patients with type 2 diabetes remains to be fully investigated in appropriate head-to-head studies

  2. ناشناس می گوید

    It’s the first time i ran through your site and I found it very informative and interesting. Nicely done!

نظرات بسته شده است.